Acquisition history Pharmatek was acquired by Catalent in 2016, signaling integration into a larger-scale contract development and manufacturing organization (CDMO) with expanded capabilities and distribution reach, presenting cross-sell opportunities to Catalent’s broader client base.

Full service CDMO Pharmatek offers end-to-end services from discovery support, analytical methods, preformulation, formulation development, cGMP manufacturing, to clinical packaging and worldwide distribution, enabling a one-stop solution for pharmaceutical and biotech partners seeking streamline outsourcing.

HP/C expertise Specialization in highly-potent and cytotoxic compounds presents a niche value proposition for clients developing potent oncology drugs or hazardous biologics, with potential to upsell advanced containment, safety, and regulatory consulting.

Moderate revenue niche With annual revenue in the $25–50 million range and 51–200 employees, Pharmatek sits between mid-sized CDMOs and larger players, offering attractive pricing leverage and personalized service for mid-market pharma and biotech companies seeking flexible partnerships.

Strategic fit for growth As part of a broader CDMO ecosystem under Catalent’s umbrella, Pharmatek can be positioned to collaborate on specialty programs, global distribution, and accelerated timelines, targeting emerging biotech portfolios and companies requiring rapid scale-up and reliable global packaging and logistics.